An experimental Alzheimer's disease drug from Eisai (4523.T) and Biogen (BIIB.O) slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients ...

Richard Silverman, PhD, is a Northwestern University chemist whose name bears the building. His experimentation led to the ...

A three-year strategic plan for reducing the risk of dementia, including Alzheimer's, and for caring for the people affected ...

Chinese scientists have demonstrated that simple, non-invasive sound therapy can produce significant and remarkably long-lasting biological changes in aged monkeys, offering new hope for a potential ...

The FDA has accepted an investigational new drug application for an investigational and proprietary combination therapy to ...

Talking to aging parents and other family members about dementia can be tricky and uncomfortable but the Alzheimer Society of BC is urging you to have that conversation. Ashley Sharma speaks with ...

Expert stakeholders establish use cases, minimum acceptable performance standards, and ideal test characteristics to support early detection, diagnosis, and characterization of cognitive impairment ...

Find out more about how blood from older donors may speed Alzheimer’s progression and what this means for future therapies.

Alzheimer’s disease biomarkers measured from finger-prick dried blood samples closely match standard plasma tests and predict ...

Tom Nolan reviews this week’s research Whenever flu hits the headlines, as it has this winter, attention inevitably turns to the flu vaccine. Might a higher dose be more effective in older adults? A ...

Digital health company Rune Labs, which helps people with Parkinson’s disease track their symptoms, said Thursday that it has appointed longtime Tempus executive Amy Gordon Franzen as CEO, and that ...

Patients with retinal vascular occlusion had an elevated risk for Alzheimer’s disease and related dementias, new research shows.